Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Partial answer to PanCan funding mystery lies with grant flo
View:
Post by Noteable on Dec 05, 2023 7:22pm

Partial answer to PanCan funding mystery lies with grant flo

The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, is thrilled that the U.S. House of Representatives approved an amendment to the Defense Appropriations Bill, increasing funding for the dedicated Pancreatic Cancer Research Program at the Department of Defense (DoD) from $15 to $20 million for the new fiscal year in their version of the bill.

The full House responded in support and the FY 24 Defense Appropriations Act was passed by the House with $20 million dedicated to pancreatic cancer research. 

 “But the money isn’t in the hands of researchers yet and we encourage Congress to work in a bi-partisan manner to complete their work on a FY 24 spending deal that includes $20 million in dedicated funding for pancreatic cancer.”


https://pancan.org/press-releases/u-s-house-of-representatives-supports-20-million-for-pancreatic-cancer-research-funding/
Comment by Noteable on Dec 07, 2023 12:08pm
The full House responded in support and the FY 24 Defense Appropriations Act was passed by the House with $20 million dedicated to pancreatic cancer research. While this is a critical milestone, PanCAN will continue to advocate to ensure the increase is included as the bill moves through next steps with the Senate and conference negotiations. “...  the money isn’t in the hands of ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities